- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Results
5
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
5 companies
China Resources Pharmaceutical Group
Market Cap: HK$29.0b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.62
7D
3.8%
1Y
-13.3%
Shanghai Haohai Biological Technology
Market Cap: HK$10.5b
Shanghai Haohai Biological Technology Co., Ltd.
6826
HK$25.70
7D
5.3%
1Y
1.2%
Tong Ren Tang Technologies
Market Cap: HK$5.8b
Produces and distributes Chinese medicine products in Mainland China and Hong Kong.
1666
HK$4.50
7D
2.0%
1Y
-8.2%
JBM (Healthcare)
Market Cap: HK$2.2b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.79
7D
4.9%
1Y
55.9%
Essex Bio-Technology
Market Cap: HK$2.2b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$3.95
7D
4.8%
1Y
41.1%